

BodyGuard Program Update

OBJ Limited (ASX: OBJ) is pleased to report that its musculoskeletal patch development, known internally as BodyGuard, has achieved several significant milestones in its ongoing development program.

Planning

Planning for the overall BodyGuard program is progressing with the first steps in the industrial design and formulation optimisation now well advanced. Further assessment of the positioning of the product in its selected market sector has been completed and reconfirms the initial positioning selected. The Company is not aware of any active patch in the market today that is able to provide the benefits offered by the BodyGuard series application. It is intended that the BodyGuard series of products will ultimately be designed for application to various body joints.

OBJ's Product Development Manager for the overall management of BodyGuard products was appointed to the position during the last quarter of 2012.

International Design

In late 2012 the Company invited several major international design houses with sports and medical design experience to tender for the design and prototype production of BodyGuard's first family of products for the treatment of various joint, ligament, tendon and cartilage injuries and degenerative conditions. The selected tenderer will be required to prepare alternative designs for the first product, material selection and testing and prepare a number of prototype products that can then be used in forthcoming clinical trials. A shortlist of candidate companies was prepared from the excellent proposals received. During March, the leading design companies were interviewed by our Product Development Manager and OBJ is now evaluating the recommendations to progress this key activity. The successful design house will be responsible for the key elements relating to look, feel and manufacturing form for the first family of BodyGuard products.

Formulation

Recent *in vitro* human skin penetration studies of OBJ's *Lubricen*[™] formulation, in conjunction with the new specially designed magnetic microarray, achieved through-the-skin delivery rates significantly greater than Europe's leading topical joint pain product.


OBJ's proprietary *Lubricen*[™]

formulation, which was designed to increase joint, tendon and ligament lubrication by mimicking natural synovial fluid aggrecans, was developed by OBJ's scientific team in conjunction with Professor Adrian Davis of the London School of Pharmacy, one of the leading topical formulation specialists.



Early BodyGuard Packaging Concept

For personal use only



Independent research has confirmed the widespread discomfort experienced by many people who undertake regular exercise and by people who suffer osteoporosis particularly as they get older. The Bodyguard active patches are intended to provide localised relief to patients rather than the commonly used systemic applications today.

Clinical Testing Programs

Clinical testing of the BodyGuard patches to demonstrate functional capabilities and superior performance is currently being planned through a number of leading Sport Science, Exercise and Healthcampuses in both Australia and Europe. Clinical testing will commence following the completion of pre-production prototype development.

Distribution

The Company will undertake this development program bringing each of the BodyGuard applications to a production stage by selecting the most efficient method of distribution through established brands or distributing the products itself.

- ENDS -

For more information:

Mr Glyn Denison	Director	Telephone	+618 9443 3011
		Email	info@obj.com.au
		Web	www.obj.com.au

About OBJ:

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.


About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ Limited

leaders in magnetic micro-array drug delivery



OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking Statements

This announcement contains certain “forward-looking statements” concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For personal use only

ABN 72 056 482 636

284 Oxford Street, Leederville 6007 Perth, Western Australia

Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960

www.obj.com.au